Chronic liver disease

Definition
Chronic liver disease (CLD) refers to a spectrum of progressive, long‑lasting disorders of the liver that result in sustained inflammation, fibrosis, and eventual loss of functional hepatic tissue. The condition persists for at least six months and may culminate in cirrhosis, liver failure, or hepatocellular carcinoma.

Epidemiology

• Global prevalence varies by cause; viral hepatitis (particularly hepatitis B and C) and non‑alcoholic fatty liver disease (NAFLD) are the most common contributors.
• According to the World Health Organization, liver disease is responsible for approximately 2 % of all deaths worldwide, with chronic forms accounting for the majority.
• Risk increases with age, male sex, obesity, alcohol consumption, and exposure to hepatotoxic agents.

Major Etiologies

1. Viral Hepatitis
   • Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
2. Alcohol‑Related Liver Disease (ARLD)
   • Prolonged excessive alcohol intake (generally >30 g/day for women, >40 g/day for men).
3. Non‑Alcoholic Fatty Liver Disease (NAFLD) / Non‑Alcoholic Steatohepatitis (NASH)
   • Associated with metabolic syndrome, obesity, type 2 diabetes, and dyslipidemia.
4. Autoimmune Hepatitis
   • Immune‑mediated destruction of hepatocytes.
5. Genetic/Metabolic Disorders
   • Examples include Wilson disease, hereditary hemochromatosis, and alpha‑1 antitrypsin deficiency.
6. Cholestatic Diseases
   • Primary biliary cholangitis and primary sclerosing cholangitis.

Pathophysiology

• Repetitive injury triggers hepatocyte necrosis/apoptosis and inflammatory cell recruitment.
• Activation of hepatic stellate cells leads to extracellular matrix deposition (fibrosis).
• Progressive fibrosis distorts hepatic architecture, impairs microcirculation, and reduces synthetic and detoxifying capacity.
• Advanced fibrosis (cirrhosis) creates portal hypertension and predisposes to liver cancer.

Clinical Manifestations

• Early/Asymptomatic Phase: Often silent; may be detected through abnormal liver function tests.
• Compensated Cirrhosis: Fatigue, mild right upper quadrant discomfort, palpable liver edge.
• Decompensated Cirrhosis: Jaundice, ascites, hepatic encephalopathy, variceal bleeding, coagulopathy.
• Associated Features: Spider angiomas, palmar erythema, gynecomastia, testicular atrophy (in men).

Diagnostic Evaluation

1. Laboratory Tests
   • Liver enzymes (ALT, AST), alkaline phosphatase, gamma‑glutamyl transferase, bilirubin, albumin, INR.
   • Serologies for HBV, HCV, autoimmune markers (ANA, ASMA), metabolic panels (iron studies, ceruloplasmin).
2. Imaging
   • Ultrasound (first‑line), elastography (FibroScan) for fibrosis assessment, CT or MRI for tumor surveillance.
3. Histology
   • Liver biopsy remains the reference standard for definitive staging in selected cases.
4. Non‑Invasive Scores
   • APRI, FIB‑4, and NAFLD fibrosis score provide estimations of fibrosis severity.

Management

• Etiology‑Specific Therapy
  • Antiviral agents for HBV/HCV (e.g., nucleos(t)ide analogues, direct‑acting antivirals).
  • Alcohol abstinence programs, pharmacologic support (acamprosate, naltrexone).
  • Weight loss, insulin sensitizers (e.g., pioglitazone), and vitamin E for NASH.
  • Immunosuppression (prednisone, azathioprine) for autoimmune hepatitis.
  • Chelation (penicillamine) for Wilson disease; phlebotomy for hemochromatosis.
• General Liver Support
  • Nutritional optimization, avoidance of hepatotoxins, vaccination against hepatitis A/B and pneumococcus.
• Complication Management
  • Diuretics and paracentesis for ascites, non‑selective beta‑blockers or endoscopic band ligation for varices, lactulose/rifaximin for encephalopathy.
  • Surveillance ultrasound ± α‑fetoprotein every 6 months for hepatocellular carcinoma in at‑risk patients.
• Advanced Disease
  • Liver transplantation is indicated for selected patients with decompensated cirrhosis, refractory complications, or early hepatocellular carcinoma.

Prognosis

• Prognosis depends on underlying cause, stage of fibrosis, and presence of complications.
• Tools such as the Model for End‑Stage Liver Disease (MELD) score predict short‑term mortality and guide transplant eligibility.
• Early detection and effective treatment of the causal factor markedly improve survival and may halt or reverse fibrosis in certain contexts (e.g., viral eradication, sustained weight loss).

Prevention

• Vaccination against hepatitis B, safe injection practices, screening of blood products.
• Public health measures to reduce alcohol misuse.
• Lifestyle interventions targeting obesity, physical inactivity, and unhealthy diet to mitigate NAFLD risk.

References (selected)

• World Health Organization. Global hepatitis report 2022.
• European Association for the Study of the Liver (EASL). Clinical Practice Guidelines: Management of NAFLD, 2023.
• American Association for the Study of Liver Diseases (AASLD). Guidelines for the treatment of hepatitis C, 2023.

This entry presents an objective overview of chronic liver disease based on current medical literature.